Aclaris Therapeutics IncNASDAQ:ACRS
- LAST PRICE3.7500
- TODAY'S CHANGE (%)-0.2400 (-6.0150%)
- Bid / Lots3.7400/ 4
- Ask / Lots3.7600/ 2
- Open / Previous Close3.9300 / 3.9900
- Day Range
- 52 Week Range
- Volume620,678
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACRS |
|---|---|---|
| 09:32 ET | 10112 | 3.95 |
| 09:33 ET | 7395 | 4.025 |
| 09:35 ET | 19550 | 4.11 |
| 09:37 ET | 25870 | 4.08 |
| 09:39 ET | 8102 | 4.07 |
| 09:42 ET | 4493 | 4.0401 |
| 09:44 ET | 5468 | 4.0685 |
| 09:46 ET | 7569 | 4.035 |
| 09:48 ET | 10558 | 4.03 |
| 09:50 ET | 1721 | 4.0593 |
| 09:51 ET | 16498 | 4.06 |
| 09:53 ET | 9425 | 4.09 |
| 09:55 ET | 3360 | 4.065 |
| 09:57 ET | 2100 | 4.05 |
| 10:00 ET | 2154 | 4.05 |
| 10:02 ET | 1100 | 4.05 |
| 10:04 ET | 7778 | 4.0063 |
| 10:06 ET | 13181 | 3.96 |
| 10:08 ET | 6606 | 3.965 |
| 10:09 ET | 487 | 3.9762 |
| 10:11 ET | 6846 | 3.925 |
| 10:13 ET | 12496 | 3.9 |
| 10:15 ET | 6182 | 3.9 |
| 10:18 ET | 5118 | 3.9 |
| 10:20 ET | 2429 | 3.8994 |
| 10:22 ET | 7276 | 3.93 |
| 10:24 ET | 2159 | 3.9 |
| 10:26 ET | 3174 | 3.9 |
| 10:27 ET | 1000 | 3.89 |
| 10:29 ET | 498 | 3.8989 |
| 10:31 ET | 700 | 3.895 |
| 10:33 ET | 1994 | 3.891 |
| 10:36 ET | 1023 | 3.885 |
| 10:38 ET | 4336 | 3.87 |
| 10:40 ET | 2409 | 3.88 |
| 10:42 ET | 100 | 3.88 |
| 10:45 ET | 2361 | 3.89 |
| 10:47 ET | 12116 | 3.87 |
| 10:49 ET | 22045 | 3.775 |
| 10:51 ET | 10345 | 3.77 |
| 10:54 ET | 10590 | 3.73 |
| 10:56 ET | 24245 | 3.74 |
| 10:58 ET | 122541 | 3.732 |
| 11:00 ET | 4079 | 3.75 |
| 11:02 ET | 4242 | 3.755 |
| 11:03 ET | 9302 | 3.745 |
| 11:05 ET | 60344 | 3.76 |
| 11:07 ET | 12153 | 3.75 |
| 11:09 ET | 3313 | 3.75 |
| 11:12 ET | 7364 | 3.76 |
| 11:14 ET | 3967 | 3.77 |
| 11:16 ET | 10933 | 3.78 |
| 11:18 ET | 5744 | 3.75 |
Nov 19, 2024
DJ Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News, from 2:21PM ET on Tuesday Nov 19, 2024 by Dow Jones
2:21PM ET on Tuesday Nov 19, 2024 by Dow JonesDJ Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners, from 8:42AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:42AM ET on Tuesday Nov 19, 2024 by Dow JonesDJ Aclaris Therapeutics Raised to Buy From Hold by Jefferies, from 8:23AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:23AM ET on Tuesday Nov 19, 2024 by Dow JonesDJ Aclaris Therapeutics Raised to Buy From Neutral by BTIG, from 4:56AM ET on Tuesday Nov 19, 2024 by Dow Jones
4:56AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 18, 2024
DJ Aclaris Therapeutics Raised to Overweight From Neutral by Piper Sandler, from 4:40PM ET on Monday Nov 18, 2024 by Dow Jones
4:40PM ET on Monday Nov 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aclaris Therapeutics Inc | 271.4M | -7.2x | --- |
Artiva Biotherapeutics Inc | 272.0M | 0.0x | --- |
Mersana Therapeutics Inc | 252.0M | -3.5x | --- |
C4 Therapeutics Inc | 300.0M | -2.5x | --- |
TScan Therapeutics Inc | 240.7M | -4.3x | --- |
Uniqure NV | 281.7M | -1.2x | --- |
Company Information
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Contact Information
- Headquarters
- 701 Lee Road, Suite 103WAYNE, PA, United States 19087
- Phone
- 484-324-7933
- Fax
- 302-655-5049
Executives
- Non-Executive Chairman of the Board, President, Interim Chief Executive Officer, Co-Founder
- Neal Walker
- President, Chief Operating Officer, Director
- Hugh Davis
- Chief Financial Officer
- Kevin Balthaser
- Chief Scientific Officer
- Joseph Monahan
- Chief Business Officer
- James Loerop
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $271.4M |
|---|---|
Revenue (TTM) | $27.1M |
Shares Outstanding | 71.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-0.52 |
Book Value | $2.22 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -170.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
